SORAFENIB IN HCC: REAL CLINICAL PRACTICE. LITERATURE REVIEW

I.I. Abdullin1, K.V. Menshikov1,2, A.V. Sultanbaev1,2, E.V. Popova1, O.N. Lipatov2

1Republican Clinical Oncology Dispensary, Ufa

2Bashkir State Medical University, Ufa

Abdullin Ilyas I. ― oncologist of the outpatient antitumor drug therapy department of the Republican Clinical Oncology Dispensary

73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: ilyas.abdullin.99@mail.ru, ORCID ID: 0009-0009-8470-4606

Abstract. Currently, sorafenib is a first-line drug for the treatment of patients with advanced hepatocellular carcinoma (HCC). It is a tyrosine kinase inhibitor that has angiogenesis-inhibiting and cell proliferation-inhibiting effects.

The drug has shown a significant slowdown in the progression of hepatocellular carcinoma and an increase in patient survival from 7,9 months to 10,7.

However, resistance and adverse events in the form of diarrhea, skin rashes, arterial hypertension and other manifestations to sorafenib remain a serious problem in the clinic. Therefore, it is urgent to elucidate the mechanisms underlying resistance and adverse events to sorafenib to develop new treatment strategies for advanced HCC.

The purpose of this review is to provide the most current clinical data on the efficacy and safety of sorafenib in patients with liver cancer.

Key words: sorafenib, hepatocellular carcinoma, treatment, inhibitor.